Lipitor Lawsuit News: Federal Court Overseeing Lipitor Diabetes Litigation Issues Order Pertaining to Discovery and Bellwether Trials, Bernstein Liebhard LLP Reports

The Firm is evaluating Lipitor lawsuits on behalf of patients whose use of the statin drug allegedly caused Type 2 diabetes.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Free Case Review
We have heard from numerous individuals concerned that their use of Lipitor caused diabetes. We are pleased to see that this litigation is progressing.

New York, New York (PRWEB) May 10, 2014

Hundreds of Lipitor lawsuits (http://www.thelipitorlawsuit.com/) that claim the statin drug caused patients to suffer Type 2 diabetes continue to move forward in the U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. Among other things, a Case Management Order issued on April 25, 2014, establishes a plan and procedures for discovery, and sets the stage for the proceeding’s first bellwether trials. According to the Order, the first of those trials could begin in July 2015. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)

“We have heard from numerous individuals concerned that their use of Lipitor caused diabetes. We are pleased to see that this litigation is progressing,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit reviews to individuals who took the statin and later developed Type 2 diabetes.

Lipitor Diabetes Allegations
According to court documents, the litigation involving Lipitor diabetes allegations has been growing since February 2012, when the U.S. Food & Drug Administration (FDA) ordered the manufacturers of statins to update their labels with information about the drugs’ potential association with Type 2 diabetes. The request followed the publication of a study in JAMA: Internal Medicine the previous month which suggested that post-menopausal women treated with statins faced an increased risk of developing new-onset Type 2 diabetes. *

Court records indicate that at least 460 Lipitor lawsuits are now pending in the District of South Carolina. All of the claims allege that Pfizer Inc. was aware of the link between Lipitor and diabetes before modifying the drug’s label in February 2012 to reflect this risk, but concealed this information in order to protect sales of the medication. The lawsuits further allege that the modified label warnings remain inadequate.

Bellwether trials like those discussed in the April 25th Case Management Order mark an important milestone in these types of litigations. Among other things, the outcomes of bellwether cases may provide insight into how juries might decide other Lipitor lawsuits.

Lipitor patients who allegedly developed Type 2 diabetes due to their use of the statin medication may be entitled to compensation. To find out more about the federal Lipitor diabetes litigation, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to obtain a free legal review.

*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993? As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.thelipitorlawsuit.com/
https://plus.google.com/115936073311125306742?rel=author